# Retreatment of patients with chronic hepatitis C, subtype 3a, and cirrhosis, who previously failed a regimen containing second-generation NS5A inhibitors with sofosbuvir + glecaprevir/pibrentasvir and ribavirin for 16–24 weeks

## TL;DR

This study examines the effectiveness of retreatment for hepatitis C patients who previously failed a specific drug regimen.

## Contribution

The study shows that using sofosbuvir + glecaprevir/pibrentasvir with ribavirin is effective for retreatment regardless of prior resistance mutations.

## Key findings

- SOF+GLE/PIB+RIB treatment for 16–24 weeks is effective for retreatment of hepatitis C subtype 3a with cirrhosis.
- NS5A resistance mutations like Y93H do not affect the likelihood of achieving a sustained virological response.
- Pibrentasvir is recommended as the first choice for retreatment after velpatasvir failure.

## Abstract

The outcomes of retreatment patients infected with hepatitis C virus genotype 3, cirrhosis, with velpatasvir may be affected by treatment failure with velpatasvir. The efficacy of SOF+GLE/PIB+RIB 16–24 weeks of treatment has been shown. The presence of NS5A resistance-associated substitution mutations, including Y93H, and the number and regimens of the past failed therapy do not influence the likelihood of achieving sustained virological response. When velpatasvir treatment fails, pibrentasvir should be used as the first choice for retreatment.